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Abstract: In the eukaryotic cell a number of molecular mechanisms exist to regulate the nature and quantity of transcripts 
intended for translation. For monogenic diabetes an understanding of these processes is aiding scientists and clinicians in 
studying and managing this disease. Knowledge of RNA processing and mRNA surveillance pathways is helping to explain 
disease mechanisms, form genotype-phenotype relationships, and identifying new regions within genes to screen for muta-
tions. Furthermore, recent insights into the regulatory role of micro RNAs (miRNAs) and RNA editing in the pancreas 
suggests that these mechanisms may also be important in the progression to the diabetic state.
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Introduction
The classical view of mRNA as a ‘passive’ messenger that simply transfers information from the form 
of DNA to protein has been challenged in recent years. An appreciation of the infl uence of mRNA 
stability and RNA processing in determining the nature and level of gene expression is growing, with 
their roles in an increasing number of diseases being elucidated. The aim of this article is to review the 
impact that an understanding of RNA processing and mRNA surveillance has had on monogenic dia-
betes and suggest where future developments may occur in this fi eld.
RNA processing
Following transcription, a pre-mRNA molecule is capped, spliced and polyadenylated. Whilst the addi-
tion of a cap structure to the 5’ end seems to occur on most mRNA molecules generated by RNA Poly-
merase II (RNAPII), whether normal or aberrant, the processes of splicing and polyadenylation are 
more tightly regulated and occur at variable positions along the pre-mRNA. These mechanisms thus 
have an important role in determining the nature of the transcript, and consequently the protein or pro-
teins that may be produced.
Splicing
Most mammalian genes consist of long, non-coding sequences (introns) that are separated by short, 
coding sequences (exons). In order to generate a functional message from the DNA template the pre-
mRNA molecule composed of introns and exons must be spliced to generate the mature mRNA mol-
ecule consisting only of exons. This ‘cut and stick’ process is achieved by the coordinated action of fi ve 
small nuclear RNAs (snRNAs) and more than 60 polypeptides in a macromolecular riboprotein complex 
called the spliceosome.
The recognition of an exon is guided by four weakly conserved intronic cis-elements: the 5’ splice 
site, 3’ splice site, the polypyrimidine tract and the branch site. These sequences form, by RNA:RNA 
base pairing, bonds with U1 and U2 small nuclear ribonucleoproteins (snRNPs) that form part of the 
spliceosome. Whilst necessary these cis elements are insuffi cient for accurate splicing; additional 
regulatory sequences within or near an exon act to enhance or silence exon recognition and consequently 
its presence/absence in the spliced transcript (Fig. 1). Enhancer sequences, termed exonic splicing 
enhancers (ESEs) or intronic splicing enhancers (ISEs), act as binding sites for specifi c serine/arginine-
rich (SR) proteins. These proteins may aid in the recruitment of the U2AF component of the spliceosome 
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complex or alternatively antagonise the action of 
nearby silencer elements. Silencer sequences, 
called exonic splicing silencers (ESSs) or intronic 
splicing silencers (ISSs), may be bound by mem-
bers of the heterogeneous nuclear ribonucleopro-
teins (hnRNP) family. Several models are proposed 
to explain how these proteins inhibit exon defi ni-
tion. These include direct competition, where an 
ESE and ESS sequence overlap resulting in mutu-
ally exclusive protein binding, or nucleation 
whereby binding of one hnRNP causes subsequent 
polymerisation and occlusion of SR proteins from 
their target sites.
Alternative splicing allows for the production 
of multiple functionally distinct proteins (isoforms) 
from a single gene. It is estimated that approxi-
mately 74% of mammalian genes are alternatively 
spliced in at least one exon (Johnson et al. 2003). 
Variant transcripts might arise as a result of exon 
skipping, use of alternative 5’ or 3’ splice sites, or 
retention of an intron. Many alternative exons are 
designated by weak splicing signals; poorly defi ned 
polypyrimidine tracts are particularly common and 
have a greater requirement for SR proteins to recruit 
the U2AF complex. Regulation of alternative splic-
ing is thus strongly dependent upon the balance of 
active-to-inactive SR proteins and hnRNPs (Stamm, 
2007). Mainly regulated by phosphorylation, the 
activities of these proteins have been shown to dif-
fer in a tissue- and stage-specifi c manner (Stamm 
et al. 2005) and be dependent on extracellular 
signalling cues such as receptor-binding ligands 
(Wang et al. 1991); temperature (Poly, 1997) and 
pH (Borsi et al. 1995).
Polyadenylation
Once RNAPII encounters a highly conserved 
polyadenylation signal (typically, but not 
exclusively, AAUAAA) the multi-protein com-
plexes, Cleavage and Polyadenylation Specifi city 
Factor (CPSF) and Cleavage Stimulation Factor 
(CstF), disembark from RNAPII and transfer to 
the pre-mRNA. CPSF binds to the polyadenylation 
signal sequence and CstF to the GU-rich sequence 
20–60 base pairs 3’ to the polyadenylation signal. 
These two complexes then promote cleavage of 
the transcript approximately 35 nucleotides 
downstream of the polyadenylation signal. Upon 
cleavage, Poly (A) Polymerase (PAP) starts adding 
the polyadenosine tail of 100–250 base pairs and 
Poly (A) Binding Protein 1 (PABPN1) subsequently 
binds to this tail, helping to target the mRNA for 
nuclear export.
Alternate splicing events can result in mRNAs 
which use different polyadenylation signals and 
thus have distinct 3’ UTRs. These untranslated 
regions can contain a number of regulatory ele-
ments that affect mRNA turnover, such as AU-rich 
elements responsible for transcript stability, and 
miRNA target sequences involved in the regulation 
of mRNA translation.
mRNA surveillance
Given that errors do arise in transcripts, it would 
be tempting to speculate that cells could be fi lled 
with defective mRNAs, which have the potential 
to be translated into aberrant proteins (Fasken 
and Corbett, 2005). However cells avoid the 
Figure 1. Splicing control elements. Recognition of an exon is guided weakly by four cis-elements;  the splice donor (GT), splice acceptor 
(AG), polypyrimidine tract (Py(n)) and branch Point (A) sequences. These are bound by the U1 and U2 small nuclear ribonucleproteins 
(snRNps) and the U2 auxillary factor protein (U2AF). Splicing regulatory (SR) proteins and heterogeneous nuclear ribonucleoproteins 
(hnRNPs) bind to enhancer (ESE/ISE) or silencer (ESS/ISS) elements and enhance or negate the recruitment of the U2AF component of 
the spliceosome to the polypyrimidine tract.
205
Splicing, nonsense-mediated decay and monogenic diabetes
Gene Regulation and Systems Biology 2008:2 
accumulation of many defective mRNAs by 
using a variety of quality control mechanisms, 
such as Nonsense-Mediated Decay (NMD) and 
Nonstop Decay (NSD).
The translation-dependent pathway, NMD, 
selectively degrades transcripts bearing a 
premature termination codon (PTC). About one-
third of genetic and acquired diseases are believed 
to be the result of a PTC (Kuzmiak and Maquat, 
2006). It is thought that NMD occurs when not 
all exon-junction complexes (EJCs), which are 
deposited on exon-exon borders during splicing, 
are removed by a pioneer round of translation in 
the nucleus. When navigating along a transcript 
without a PTC, the ribosome is believed to 
displace or remodel all EJCs. However if a tran-
script has a PTC, none of the EJCs 3’ to this mark 
are removed, and this serves as a signal for bind-
ing of the Up-frameshift (UPF) proteins to the 
transcript. These proteins mark the transcript for 
degradation through two main pathways; the 
5’-3’ Xrn1 and 3’-5’ exosome-dependent pathways 
(Fig. 2) (Baker and Parker, 2004).
Recognition of a nonsense codon by the NMD 
pathway may also modulate the splicing machin-
ery to eliminate production of transcripts bearing 
the PTC. In nonsense-associated altered splicing 
(NAS), the splicing of the pre-mRNA is modifi ed 
so that the exon carrying the nonsense mutation 
is not included in the mature transcript. This may 
confer a selective advantage by allowing a pro-
tein of residual function to be made, which has 
been documented to moderate Duchenne mus-
cular dystrophy (DMD) (Disset et al. 2006). 
Alternatively the splice variant may have delete-
rious consequences by acting in a dominant-
negative fashion. Most frequently however NAS 
is likely to result in a change in the reading frame 
which in turn triggers NMD anyway. Several 
mechanisms are proposed to explain NAS, one 
suggesting the existence of a nuclear mRNA 
surveillance system distinct from the NMD 
machinery that verifi es the integrity of an ORF. 
This, when necessary, directs the splicing 
machinery to skip the offending exon (Cartegni 
et al. 2002).
In contrast to NMD the nonstop decay (NSD) 
pathway recognises mRNAs that lack a termina-
tion codon resulting in abnormally extended 
transcripts. Whilst it is known that the mutant 
transcript is recognised and degraded by the Ski 
complex and cytoplasmic exosome (Fasken 
and Corbett, 2005), this pathway is not well 
characterised in humans, partly due to the rarity 
Figure 2. Nonsense-mediated decay model. As a ribosome navigates along a transcript it is believed to remodel or displace the exon junction 
complexes. If, upon translating a premature termination codon, any exon junction complexes are left 3’ to this mark UPF proteins bind to the 
transcript. This serves to target the transcript for degradation by exonucleases.
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of mutations that result in ribosomal read-through 
of termination codons.
Monogenic diabetes
As Type 2 diabetes reaches epidemic proportions 
it is worth restating that it is a diagnosis of exclu-
sion, and that around 1%–2% of cases are likely 
to have a monogenic form of diabetes (Gloyn and 
Ellard, 2006). Recent progress in defi ning genes 
causing two forms of monogenic diabetes—matu-
rity onset diabetes of the young (MODY) and 
neonatal diabetes (NDM)—are having profound 
implications on patient care and also providing 
fascinating insights into the aetiology of the more 
common Type 2 diabetes.
Maturity-onset diabetes of the young (MODY) 
is an autosomal dominant form of inherited diabe-
tes characterised by beta-cell dysfunction. Patients 
presenting with the disease are usually slim, diag-
nosed at an early age (typically, but not exclusively 
<25 years) and not insulin-dependent (although 
insulin treatment may be required in the later stages 
of the disease). In ∼89% of MODY cases a muta-
tion in one of seven genes (HNF1A, HNF4A, 
HNF1B, GCK, NEUROD1, IPF1, and CEL) has 
been found (Frayling et al. 2001).
Neonatal diabetes is now defi ned as hypergly-
caemia presenting within the fi rst 6 months of life 
(Massa et al. 2005). Around 50% of these cases 
will have transient neonatal diabetes (TNDM) 
where diabetes resolves within this time frame 
(Gloyn and Ellard, 2006). TNDM is most com-
monly associated with abnormalities of an 
imprinted locus on chromosome 6q24 (Temple 
et al. 2000). The remaining half of cases will not 
resolve and are termed to have permanent neonatal 
diabetes (PNDM) where treatment is required for 
life. Approximately 41% of PNDM cases are 
caused by heterozygous activating mutations in 
either KCNJ11 or ABCC8, the genes encoding the 
KATP channel subunits, Kir6.2 and SUR1 (Edghill 
et al. 2008). The KATP channel plays a key role in 
insulin secretion and functional characterisation of 
activating mutations in the Kir6.2 and SUR1 sub-
units have shown that mutant channels have a 
reduced sensitivity to ATP. This results in a failure 
of the KATP channel to close in response to ATP, 
and ultimately, the pancreatic beta cell to secrete 
insulin effectively. It has been recently identifi ed 
that ∼20% of PNDM cases are caused by mutations 
in the INS gene (Stoy et al. 2007).
The Role of RNA Processing
in Monogenic Diabetes
Isoforms of HNF1A and HNF4A 
have an ability to moderate
MODY phenotype
The HNF1A, HNF4A and HNF1B genes encode 
for multiple isoforms which are generated by a 
combination of alternate splicing, polyadenylation 
and promoter-usage events. The HNF1A gene 
codes for three isoforms that are identical in their 
DNA binding and dimerisation properties but have 
different transactivation potentials. The expression 
of these isoforms has been shown to differ in a 
temporal and spatial manner (Harries et al. 2006). 
Whilst HNF1A(A) is believed to be the most com-
mon isoform in most tissues (Bach and Yaniv, 
1993), HNF1A(B) is predominant in both total 
adult pancreas and isolated islet cells. Levels of 
HNF1A(C) are also higher in these adult tissues 
(Harries et al. 2006).
The regulated expression of these isoforms sug-
gested a functional role, particularly in tissues with 
high expression (i.e. the pancreas). Harries et al. 
hypothesised that mutations that affect only certain 
HNF1A isoforms might lead to different infl uences 
on beta-cell dysfunction and subsequently diabetic 
phenotype. In a cohort of 564 HNF1A MODY 
patients with 123 different mutations age of diag-
nosis was related to mutation position and isoform 
structure. We found that patients with a missense 
mutation in the fi rst six exons, affecting all iso-
forms, presented with diabetes an average of 
12 years before patients with a missense mutation 
in exons 8–10, which would only affect HNF1A(A) 
(Harries et al. 2006). This provided further proof 
for a functional role of isoforms HNF1A(B) and 
(C) in the pancreas.
A similar situation has been subsequently shown 
with regards to HNF4A mutation position and age 
of diagnosis (Harries et al. 2008). Patients with a 
mutation in exon 9 or 10 of HNF4A (that does not 
affect isoforms HNF4A(3), (6) or (9)) present at a 
median age of 40. This is 16 years later than the 
median age of onset for patients with a mutation 
in exons 2–8, that affects all isoforms. Perhaps of 
more interest to the clinical setting was the analy-
sis relating mutation position to age-related pen-
etrance. Using a Kaplan-Meier analysis it was 
shown that by 55 years of age 53% of patients with 
a mutation in exons 9 and 10 had not gone on to 
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develop diabetes compared with just 9% of patients 
with a mutation in exons 2–8. These fi ndings have 
important consequences for the management and 
monitoring of families with less penetrant muta-
tions. This study also challenges the longstanding 
defi nition of MODY as a disease that will typically 
present within the fi rst 25 years of life.
Discovering new areas to screen
for mutations
When screening a gene for disease-causing mutations 
intronic variants outside the conserved splice donor 
and acceptor sites are often overlooked as being 
potentially pathogenic. In genetic testing for MODY 
there seems to be an awareness for the potential 
of mutations to affect cis elements regulating 
constitutive splicing, outside the conserved 5’ and 
3’ splice sites. For example the HNF1A IVS7–6G>A 
mutation was shown to result in the generation of an 
alternative splice acceptor site and a frameshift that 
resulted in a PTC (Bulman et al. 2002).
An increasing appreciation for the importance 
of alternate RNA processing in the HNF genes also 
opens up new gene regions in which to screen for 
mutations causing MODY. The fi nding that the 
predominant HNF4A isoforms in the adult pancreas 
are transcribed from an alternative promoter (P2) 
to that in the adult liver (P1) highlighted a new area 
to screen. Also involving an alternative splicing 
event, with the alternate fi rst exon (exon 1D) spliced 
to exon 2, mutations in the P2 promoter and exon 
1D have subsequently been shown to cause MODY 
(Thomas et al. 2001; Ellard and Colclough, 2006). 
No mutations in the P1 promoter and exon 1A, 
coding in isoforms predominantly expressed in the 
liver, have been found to cause MODY. This 
stresses the need to determine expression profi les 
of isoforms when embarking on genetic testing.
Both HNF1A(B) and HNF1A(C) contain novel 
amino acids derived from intronic sequences and it 
seems plausible that mutations in these regions, not 
currently screened by sequencing, could cause 
MODY. Despite having truncated transactivation 
domains these shorter isoforms have been shown to 
possess higher transactivation activities than the full 
length transcript (HNF1A(A)) (Bach and Yaniv, 
1993). The two shorter isoforms also provide 
approximately 75% of HNF1A expression in the 
adult pancreas. Similarly the translated intronic 
sequences in certain HNF1B and HNF4A isoforms 
might also be investigated for possible mutations. 
The report by Harries et al. suggests an important 
role for HNF4A(3) in the pancreas and so mutations 
causing MODY may be found in IVS8, part of which 
is coding in this isoform (Harries et al. 2008).
An understanding of splicing helps 
to explain the molecular mechanisms 
causing the disease
HNF1B gene mutations affect development of the 
kidneys and pancreas, resulting in renal develop-
mental abnormalities, reduced birth weight and 
diabetes in later life (Bingham and Hattersley, 2004; 
Edghill et al. 2006). The most common renal 
manifestation is renal cysts which are frequently 
diagnosed on antenatal ultrasound. This syndrome 
is known as renal cysts and diabetes (RCAD), but 
can also include female genital tract malformations, 
gout and liver disease (Bingham and Hattersley, 
2004). The fi nding that the HNF1B gene encodes 
an isoform that acts as a transcriptional repressor 
(HNF1B(C)) may explain why most mutations in 
this gene are in exons 1–4. HNF1B(C) is transcribed 
from only these four exons and one would postulate 
that a mutation in one of these exons would inac-
tivate it. A missense mutation elsewhere in the gene 
would not affect the repressor and could lead to loss 
of HNF1B activity not only from the mutant allele 
but also sequestration of product from the wild-type 
allele in inactive dimers with HNF1B(C). Whilst 
missense mutations in exons 5–10 have not been 
shown to cause RCAD insertion/deletion mutations 
have been reported. These mutations were shown 
to be highly susceptible to NMD (Harries et al. 
2005) and would result in some reduction of 
HNF1B(C) levels. This idea that slight overexpres-
sion of full-length HNF1B causes a decrease in 
insulin secretion is supported by studies in rat 
INS-1 cells. Conditional expression of HNF1B led 
to loss of the insulin secretory response whilst 
expression of a dominant-negative form did not 
(Welters et al. 2006).
Determining the functional effect of mutations 
in GCK has centred around their effect on protein 
kinetics and stability. Indeed the majority of muta-
tions in GCK seem to exert their deleterious effect 
through reducing protein stability or reducing the 
enzymes affi nity for glucose. However certain 
mutations such as A53S, H137R and R275C seem 
to show normal protein characteristics (Matschinsky, 
2002). Several theories abound as to how these 
mutations cause MODY. One such reason might 
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be their ability to cause aberrant splicing through 
disruption of ESE sequences. Approximately 15% 
of ‘missense’ mutations are thought to exert their 
effect through altered splicing rather than protein 
function (Nissim-Rafi nia and Kerem, 2005).
mRNA Surveillance and Monogenic 
Diabetes
An understanding of NMD helps to 
explain the molecular mechanisms 
causing the disease
As MODY is an autosomal dominant disease, 
where only one allele is mutated, it had been pro-
posed that the clinical phenotype be caused either 
by haploinsuffi ciency or by a dominant-negative 
effect of the mutated protein upon the wild-type 
protein. Whilst initial in vitro characterisation of 
the common P291fsinsC mutation in HNF1A sug-
gested a dominant-negative mechanism (Yamagata 
et al. 1998), it has been subsequently shown that 
MODY is most likely a disease of haploinsuffi -
ciency (Harries et al. 2004). Clues for this came 
from the similar phenotypes of patients with 
HNF1A MODY due to loss-of-function mutations 
(e.g. promoter or dimerisation domain mutations) 
and patients with the initially presumed dominant-
negative P291fsinsC mutation. Furthermore the 
demonstration that NMD results in the destruction 
of several transcripts bearing PTCs, and that whole 
HNF1A gene deletions have been documented to 
cause MODY, proves it is a haploinsuffi ciency 
syndrome. RCAD caused by HNF1B mutations is 
also likely to be a disease of haploinsuffi ciency as 
whole gene deletions of HNF1B have been docu-
mented (Edghill et al. 2007), and a number of 
mutations in HNF4A have also been shown to be 
loss-of-function (Yang et al. 2000).
One must be careful though when stating whether 
a disease is one characterised solely by haploinsuf-
fi ciency or dominant-negative mechanisms. The 
numerous reports documenting differences in the 
degree of NMD shows that it is not an all-or-nothing 
process (Wang et al. 2002; Inacio et al. 2004; Harries 
et al. 2005). A percentage of PTC-containing tran-
scripts will remain, with this number often related 
to the position of the PTC within the gene. As a 
result different mutations can vary quite markedly 
in their susceptibility to NMD. In addition to NMD, 
translation reinitiation events, and possible NAS, 
may also increase the number of potentially 
dominant-negative proteins produced. In one 
diabetic family with an IPF-1 frame shift mutation 
a novel isoprotein has been shown to be generated 
as a result of translation reinitiation. It was subse-
quently shown to exert a dominant-negative effect 
on the activation of transcription by the wild-type 
protein (Stoffers et al. 1998). Despite apparently 
being a disease of haploinsuffi ciency the signifi cant 
differences in NMD susceptibility seen between 
PTC-causing mutations in HNF1B suggests domi-
nant-negative proteins may be generated. Indeed 
examination of the 5’ end of the gene shows the 
presence of two potential reinitiation codons each 
displaying some conservation of the surrounding 
sequence necessary for translation (Harries et al. 
2005). Generation of truncated isoforms has the 
potential to moderate phenotype and may partly 
explain the phenotypic heterogeneity associated 
with HNF1B mutation carriers.
In PNDM an understanding of the role of NMD 
has helped explain how a mildly activating ABCC8 
mutation can result in diabetes when a loss-of-
function mutation is inherited on the other allele. In 
a patient who had inherited a frameshift mutation 
on one allele and a mildly activating mutation on 
the other, NMD was shown to result in signifi cant 
degradation of the transcript from the frameshift 
allele. As a result it was proposed that the vast major-
ity of pancreatic KATP channels would be homomeric 
for the missense mutation. This was the fi rst reported 
disease phenotype to be caused by compound het-
erozygosity for both gain-of-function and loss-
of-function mutations (Ellard et al. 2007).
Future Considerations
MicroRNAs
MicroRNAs (miRNAs) are short 21–22 nucleotide 
RNA molecules that bind in a sequence-specifi c 
manner to the 3’ untranslated region (UTR) of 
target mRNAs. Believed to be dependent on the 
miRNA-mRNA sequence match, this association 
either impairs translation initiation or causes 
mRNA degradation. miRNAs have been shown to 
regulate genes involved in a myriad of cell pro-
cesses such as apoptosis, proliferation, differen-
tiation and neuronal cell fate (Gauthier and 
Wollheim, 2006). They have also been associated 
with cancer and neurological disorders (Jin et al. 
2004; Lu et al. 2005).
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In a study by Poy et al. the pancreatic islet-
specifi c miRNA, miR-375, was shown to regulate 
insulin exocytosis, pointing to a possible involve-
ment of microRNAs in diabetes (Poy et al. 2004). 
Using a siRNA homologous to miR-375 it was 
shown that insulin secretion was significantly 
impaired, to a level similar to that of siRNA-
mediated knockdown of GCK. This was one of the 
fi rst accounts of a single miRNA having a measur-
able phenotypic effect. It had previously been 
thought that miRNAs had overlapping functions 
each only acting to ‘fi ne-tune’ gene expression 
(Stark et al. 2005). Subsequently miR-9 and miR-
124a have been implicated in regulating insulin 
secretion and intracellular signalling pathways in 
beta cells (Plaisance et al. 2006; Baroukh et al. 
2007). miR-375 has also been shown to play a 
crucial role in maintaining normal islet cell 
architecture during embryonic development 
(Kloosterman et al. 2007). A mouse conditional 
knockout of the miRNA-processing enzyme, 
Dicer1, specifi cally in early pancreas development 
leads to signifi cant beta cell loss (Lynn et al. 2007). 
Given the signifi cant role of several microRNAs 
in the pancreas it may be that mutations in miRNA 
genes could cause a monogenic form of diabetes. 
Indeed it may be worth revisiting MODY linkage 
scans, where no causative protein-coding gene was 
found, for possible miRNA involvement.
If mutations in miRNAs or their target sites do 
not directly cause diabetes information regarding 
their target genes may however be of use. Combin-
ing data from expression profi les of miRNAs and 
their target mRNAs may help in constructing a 
more considered list of candidates to screen as 
possible disease-causing genes. Recent techno-
logical advances mean that spatial and temporal 
profi ling of all known human miRNAs can be done 
easily and quickly. This can be combined with our 
knowledge that specifi c miRNAs target genes 
involved in the same complex cell processes, e.g. 
insulin exocytosis. For example, if a miRNA was 
shown to target all members of the HNF family 
causing MODY and another gene also expressed 
largely in beta cells then this gene might become 
a strong candidate gene. Several of the HNF 
isoforms do possess long (>1000 bp) 3’UTRs 
which contain multiple predicted miRNA binding 
sites. HNF1B is a particularly likely candidate for 
miRNA regulation as whilst its transcripts are 
abundantly present in adult pancreatic islets 
there seems to be limited expression of this 
protein in mature beta cells (Maestro et al. 2003). 
miRNA-mediated regulation of HNF1B is likely 
to be a sensible way of tightly regulating HNF1B 
protein levels. Too much HNF1B is associated with 
apoptosis and a decrease in insulin secretion 
(Welters et al. 2006) whilst lack of expression is 
known to cause hyper proliferation and is associ-
ated with clear-cell and ovarian carcinomas 
(Rebouissou et al. 2005; Terasawa et al. 2006).
RNA editing
RNA editing through the conversion of adenosine 
(A) to inosine (I) within pre-mRNAs is a genetic 
recoding process found in a variety of species 
including humans. A-to-I RNA editing is catalysed 
by a family of ubiquitously expressed enzymes, 
adenosine deaminases acting on RNA (ADARs). 
Nucleotide changes can arise in coding sequences 
and also alter pre-mRNA splicing and mRNA 
stability.
RNA editing was initially shown to play an 
essential role in the brain, regulating the activities 
of several neurotransmitter receptors and ion chan-
nels. The high similarity in cellular development, 
and expression of similar genes, suggested a role 
for A-to-I RNA editing by ADARs in the endocrine 
system. Gan et al. have shown that ADAR2 is 
signifi cantly expressed in mouse islets and further-
more that its activity is regulated by the energy 
metabolism status of the cell (Gan et al. 2006). 
They report that one of its target genes is the glu-
tamate receptor and that editing is increased in 
diet-induced obesity mice. Whether the nucleotide 
changes resulted in any alteration in glutamate 
signalling and consequently insulin secretion was 
not however determined. Like microRNAs it has 
been suggested that RNA editing may control 
several components of the insulin release machinery 
(Gan et al. 2006). Combined computer-based and 
experimental advances are improving our ability 
to identify RNA editing substrates; recently C-to-U 
RNA editing sites have been predicted in silico 
with a stated 84% accuracy using solely nucleotide 
sequence features (Du et al. 2007).
Therapeutic intervention
at the RNA level
Gene silencing strategies have the potential to treat 
a variety of diseases by addressing targets that had 
previously been thought of as ‘undruggable’. The 
relative ease with which mRNA can be accessed 
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has resulted in most therapeutic efforts being 
concentrated at the RNA level (Gewirtz, 2007). 
The principle surrounding these ‘antisense’ 
technologies is essentially the same; involving the 
delivery of a strand of DNA or RNA into 
a cell that is reverse complementary to the 
mRNA encoding the protein that one would like 
to destroy.
Whilst neonatal diabetes caused by mutations 
in the KCNJ11 and ABCC8 genes seems to be suc-
cessfully controlled by high dose sulphonylurea 
treatment (Pearson et al. 2006; Rafi q et al. 2007) 
there is a need for more effi cacious treatment 
caused by mutations in other genes. For example, 
most INS mutations are believed to cause diabetes 
due to a loss of beta-cell function and mass, that 
is the result of the mutant dominant-negative acting 
INS allele (Stoy et al. 2007). Targeted degradation 
of mutant INS alleles might thus be advantageous. 
Recent research indicates that small interfering 
RNAs (siRNAs) could be developed to discrimi-
nate between wild-type and mutant alleles that 
differ by just a single nucleotide (Schwarz et al. 
2006). A study in mice has described the success-
ful introduction, by intravenous tail vein injection, 
of an siRNA targeting Ins2 into islet cells which 
resulted in a 33% reduction in Ins2 transcript levels 
(Bradley et al. 2005).
Being dominantly inherited diseases classically 
defined as haploinsufficiency syndromes, the 
various subtypes of MODY are perhaps not the 
most attractive candidates for antisense therapies 
that are typically aimed at decreasing transcript 
levels. Despite this there are perhaps a couple of 
avenues where therapies acting at the RNA level 
may be of use.
Firstly, frameshift-causing mutations in exons 
5–10 of HNF1B could be targeted by antisense-
mediated exon skipping. Frameshift mutations in 
these exons likely cause diabetes by producing a 
PTC which activates NMD and degradation of the 
entire mutant allele. The absence of missense muta-
tions causing MODY in exons 5–10 of HNF1B 
suggests that not all of these exons are necessary 
for correct HNF1B function. By designing antisense 
oligonucleotides against the conserved splice sites 
of these exons it may be possible to skip the non-
essential exon containing the nonsense mutation 
whilst maintaining the correct reading frame. 
Encouraging results for this exon skipping tech-
nique have been reported in a Duchenne muscular 
dystrophy mouse model with a nonsense mutation 
in exon 23 of the dystrophin gene (Lu et al. 
2005).
Secondly, a new molecular weight compound, 
called PTC124, is being developed that could be 
used to treat multiple diseases caused by nonsense 
mutations. PTC124 increases levels of transcript 
originating from a mutant allele harbouring a PTC 
by promoting ribosomal readthrough of the non-
sense mutation, thus decreasing NMD. Inducing 
readthrough of premature, but not normal termina-
tion codons, this drug has been shown to rescue 
striated muscle function in mice modelling Duch-
enne muscular dystrophy within 2–8 weeks of drug 
exposure (Welch et al. 2007).
Concluding Remarks
The need to maintain strict control of HNF1A, 4A 
and 1B protein levels can be evidenced by the 
number of phenotypes associated with varied 
expression of these transcription factors. Variation 
in the P2 promoter of HNF4A, presumably leading 
to a decrease in HNF4A expression, has been asso-
ciated with an increased risk of developing Type 2 
diabetes (Weedon et al. 2004), whilst bi-allelic 
inactivation of HNF1A and HNF1B has been shown 
to cause a number of types of cancer (Bluteau et al. 
2002; Terasawa et al. 2004; Rebouissou et al. 2005). 
As it has for monogenic diabetes, continued 
research in the area of RNA processing and mRNA 
surveillance may provide fascinating insights into 
the pathogenesis behind these diseases as well as 
other diabetes-related phenotypes such as renal 
disease and hyperinsulinaemic hypoglycaemia.
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